<http://schema.org/description>
"The new combination agent TAS-102 is able to improve overall survival compared to placebo in patients whose metastatic colorectal cancer is refractory to standard therapies, researchers said at the ESMO 16th World Congress on Gastrointestinal Cancer in Barcelona."^^<http://www.w3.org/2001/XMLSchema#string>
<http://medicalxpress.com/news/2014-06-survival-tas-mets-colorectal-cancer.html>